Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Cash & Equivalents (2016 - 2024)

Historic Cash & Equivalents for Sanofi (SNY) over the last 17 years, with Q3 2025 value amounting to $10.4 billion.

  • Sanofi's Cash & Equivalents rose 2165.33% to $10.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 billion, marking a year-over-year increase of 2165.33%. This contributed to the annual value of $9.3 billion for FY2024, which is 121.31% down from last year.
  • As of Q3 2025, Sanofi's Cash & Equivalents stood at $10.4 billion, which was up 2165.33% from $17.4 billion recorded in Q2 2025.
  • In the past 5 years, Sanofi's Cash & Equivalents ranged from a high of $17.4 billion in Q2 2025 and a low of $6.9 billion during Q1 2023
  • In the last 5 years, Sanofi's Cash & Equivalents had a median value of $10.4 billion in 2025 and averaged $10.8 billion.
  • Per our database at Business Quant, Sanofi's Cash & Equivalents crashed by 3833.53% in 2023 and then soared by 8535.54% in 2025.
  • Quarter analysis of 5 years shows Sanofi's Cash & Equivalents stood at $11.6 billion in 2021, then rose by 12.48% to $13.0 billion in 2022, then decreased by 27.88% to $9.4 billion in 2023, then dropped by 0.68% to $9.3 billion in 2024, then grew by 11.86% to $10.4 billion in 2025.
  • Its last three reported values are $10.4 billion in Q3 2025, $17.4 billion for Q2 2025, and $9.2 billion during Q1 2025.